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Background: Chronic elevation of glucose level activates vascular inflammation and increases endothelial
adhesiveness to monocytes, an early sign of atherogenesis. This study aimed to elucidate the detailed mechanisms
of high-glucose-induced endothelial inflammation, and to investigate the potential effects of Ginkgo biloba extract
(GBE), an antioxidant herbal medicine, on such inflammation.
Materials and methods: Human aortic endothelial cells were cultured in high glucose or mannitol as osmotic
control for 4 days. The expression of cytokines and adhesion molecules and the adhesiveness of endothelial cells to
monocytes were examined. The effects of pretreatment of GBE or N-acetylcysteine, an antioxidant, were also
investigated.
Results: Either high glucose or mannitol significantly increased reactive oxygen species (ROS) production,
interleukin-6 secretion, intercellular adhesion molecule-1 (ICAM-1) expression, as well as endothelial adhesiveness to
monocytes. The high-glucose-induced endothelial adhesiveness was significantly reduced either by an anti-ICAM-1
antibody or by an interleukin-6 neutralizing antibody. Interleukin-6 (5 ng/ml) significantly increased endothelial
ICAM-1 expression. Piceatannol, a signal transducer and activator of transcription (STAT) 1/3 inhibitor, but not
fludarabine, a STAT1 inhibitor, suppressed high-glucose-induced ICAM-1 expression. Pretreatment with GBE or
N-acetylcysteine inhibited high-glucose-induced ROS, interleukin-6 production, STAT1/3 activation, ICAM-1
expression, and endothelial adhesiveness to monocytes.
Conclusions: Long-term presence of high glucose induced STAT3 mediated ICAM-1 dependent endothelial
adhesiveness to monocytes via the osmotic-related redox-dependent interleukin-6 pathways. GBE reduced
high-glucose-induced endothelial inflammation mainly by inhibiting interleukin-6 activation. Future study is
indicated to validate the antioxidant/anti-inflammatory strategy targeting on interleukin-6 for endothelial
protection in in vivo and clinical hyperglycemia.
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In the early stages of atherogenesis, the adhesiveness of
vascular endothelium to monocytes is increased, which
may be mediated by endothelial expression of adhesion
molecules such as intercellular adhesion molecule 1
(ICAM-1), vascular cell adhesion molecule 1 (VCAM-1),
and others as a result of endothelial dysfunction [1].
Clinical evidence suggests that hyperglycemia is an inde-
pendent risk factor of diabetes-associated atherosclerosis
[2]. In vitro studies also suggest that high concentration
of glucose (high glucose) could induce ICAM-1 expres-
sion [3] and increase the production of chemokines such
as interleukin-6 (IL-6) through a tyrosine kinase mech-
anism involving the Janus kinase/signal transducer and
activator of transcription (JAK/STAT) pathways [4].
However, the detailed mechanisms by which high glu-
cose could induce endothelial adhesiveness have not
been fully clarified.
It was suggested that leukocyte-endothelial interaction
may be augmented by high glucose or hyperglycemia in
a NF-kB-dependent fashion [5]. It was also reported that
high glucose might induce ICAM-1 accumulation by a
non-specific osmotic effect [6]. On the other hand,
VCAM-1 expression was shown to increase in endothe-
lial cells by serum from type 1 diabetic patients but not
by high-glucose stimulation [7]. Previous studies further
indicated that the short-term presence of inflammatory
cytokines rather than high glucose could induce endo-
thelial expression of VCAM-1 and ICAM-1 [8]. Accord-
ingly, the mechanisms of high-glucose-induced
endothelial expression of adhesion molecules could be
complex. It was not known whether and how inflamma-
tory cytokines could alter endothelial expression of adhe-
sion molecules in the presence of high glucose.
Ginkgo biloba extract (GBE), an herbal medicine with
antioxidant mechanisms, has been used as a therapeutic
agent for some cardiovascular and neurological disorders
[9]. Although the exact mechanism has not been com-
pletely clarified, cumulative in vitro and in vivo evidence
suggests the protective effects of GBE in ischemia/
reperfusion injury [10] by reducing oxidative stress [11].
Our previous studies also showed that GBE may inhibit
neointimal hyperplasia [12] and cytokine-stimulated endo-
thelial adhesiveness to monocytes [13], at least in part by
inducing heme oxygenase-1 to reduce intracellular oxida-
tive stress [14]. However, it was not known whether and
how GBE could reduce high-glucose-induced endothelial
adhesiveness.
Clinical evidence suggests that endothelial adhesion
molecule expression is enhanced in the aorta and the
internal mammary artery of diabetic patients [15]. Add-
itionally, hyperglycemia-mediated adhesion of neutro-
phils to rat endothelial cells could be attenuated by
superoxide dismutase in vivo [16]. These findingssupport the hypothesis that intracellular oxidative stress
might be critical to high-glucose-mediated, diabetes-
associated atherosclerosis. The current study was con-
ducted 1) to clarify whether and how redox-related
mechanisms could contribute to high-glucose-induced
endothelial adhesiveness to monocytes, and 2) to investi-
gate whether GBE as an herbal antioxidant could reduce
in vitro endothelial adhesiveness in the presence of high
glucose. Our findings may help to further clarify the
complex mechanisms by which high glucose might in-
duce endothelial inflammation and to provide the ration-
ale to the potential role of anti-inflammatory strategy for
vascular protection in clinical hyperglycemia.Materials and methods
This in vitro study was approved by the research commit-
tee of Taipei Veterans General Hospital, Taipei, Taiwan,
Republic of China.Reagents
Endothelial cell growth medium (M200) was obtained
from Cascade Biologics (Cascade Biologics, Portland,
OR). The GBE (Cerenin) was purchased from Dr.
Willmar Schwabe (Dr. Willmar Schwabe, Inc.). 2′,7′-bis
(2-carboxyethyl)-5(6)- carboxyfluorescein acetoxymethyl
ester (BCECF-AM) and 2′,7′- dichlorofluorescein diace-
tate (DCFH-DA) were obtained from Molecular Probes
(Invitrogen/Molecular Probes). Antibodies against human
ICAM-1 and β-actin were obtained from R&D Systems
(R&D Systems) and Chemicon (Chemicon, Temecula), re-
spectively. Unless otherwise specified, all chemicals and
reagents were from Sigma (Sigma).Cell cultures and cell viability assay
HAECs (Cascade Biologics) and THP-1 from American
Type Culture Collection (Rockville) were cultured as
described previously [14]. After incubation with glucose,
mannitol, or GBE, cell viability was always found to be
greater than 95% by using the trypan blue exclusion
method or a 3-(4,5-dimethylthiazol-2- yl)-2,5-diphenyl
tetrazolium bromide (MTT) assay (Sigma).Monocyte-endothelial cell adhesion assay
The adherence of THP-1, a human monocytic cell line,
to glucose- and mannitol-activated HAECs was exam-
ined under static conditions to explore the endothelial
cell–leukocyte interaction. Adhesion assays were per-
formed as described previously [14]. HAECs were grown
to sub-confluence in 24-well plates and treated with glu-
cose or mannitol for 3 days, followed by treatment with
GBE or NAC for 1 day.
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Western blot analyses were performed using the meth-
ods as described previously [14].
Enzyme-linked immunosorbent assay (ELISA)
HAECs were continuously incubated in a high-glucose
medium with or without antioxidants for 4 days. The
levels of secreted IL-6 in the medium were determined
by ELISA with the human IL-6 kit (BioSource). The pro-
cedures were carried out according to the instructions of
the manufacturer.
Electrophoretic mobility shift assay (EMSA)
EMSA was performed as previously described [13]. The
synthetic, double-stranded oligonucleotides used in the
gel shift assay as the STAT1 and STAT3 probes were 5′-
GAT CTT CAG TTT CAT ATT ACT CTA AAT CCA
GGA TC-3′ and 5′-GAT CCC TTC GGG AAT TCC
TAG ATC-3′, respectively. For supershift analyses, anti-
STAT1 and anti-STAT3 monoclonal antibodies (Santa
Cruz) were added to the reaction mixture 60 min before
the addition of labeled oligonucleotides at 4°C.
Measurement of ROS production
ROS production in HAECs was determined by a fluoro-
metric assay using DCFH-DA as a probe to detect the
presence of H2O2. The fluorescence intensity (RFU) was
measured at an excitation wavelength of 485 nm and an
emission wavelength of 530 nm by using a fluorescent
microplate reader (VICTPR2 Multilabel Readers, USA).
Statistical analysis
All data were expressed as the mean±SEM. Intergroup
comparisons were performed by using a Student’s t test or
one-way analysis of variance (ANOVA). A p value< 0.05
was considered statistically significant.
Results
High glucose time-dependently increases ICAM-1 and IL-6
expression in HEACs
It has not been clarified which adhesion molecules such
as ICAM-1, VCAM-1 or both and which cytokines might
be involved in glucose-induced monocyte adhesion to
endothelial cells [17]. Thus, we first examined the
chronic time-dependent effects of high glucose (D-glucose,
25 mmol/l) on the expression of some adhesion molecules
including ICAM-1 and VCAM-1 and inflammatory cyto-
kines including IL-1, IL-6, and TNF-alpha in HAECs.
Western blotting analyses showed that both ICAM-1 and
IL-6 expression were significantly increased after high glu-
cose treatment for 4 days through 7 days and reduced after
14 days (Figure 1). There were no significant changes of
endothelial VCAM-1, IL-1, and TNF-alpha expression byhigh glucose treatment for up to 14 days in this in vitro ex-
periment (Data not shown).
Long-term effects of high glucose and mannitol on
endothelial cell viability, ICAM-1 expression, and
adhesiveness to monocytes
An MTT assay was conducted to investigate the cytotox-
icity effect of high glucose and mannitol, as the osmotic
control, in cultured HAECs. Exposure to D-glucose
(25 mmol/l) or mannitol (25 mmol/l) for 1, 4, and 7 days
resulted in no cytotoxicity in HAECs (Figure 2A). Western
blotting analysis showed that treatment with high glucose
or mannitol time-dependently increased ICAM-1 expres-
sion in HAECs (Figure 2B). However, the effect of high
glucose stimulation was reversible since the high-glucose-
induced expression of ICAM-1 was being reduced 1 to
4 days after the high-glucose medium was replaced by nor-
mal medium (Additional file 1: Figure S3). Further, as
shown in Figure 2C, long-tem exposure of HAECs to high
glucose for 4 days significantly increased endothelial adhe-
siveness to THP-1 cells, which was similar to the effects of
mannitol. The results suggest a common osmotic effect
that might contribute to the induction of endothelial
ICAM-1 as well as endothelial adhesiveness by high glu-
cose or mannitol. To investigate the role of ICAM-1 ex-
pression in high-glucose-induced endothelial adhesiveness
to monocytes, glucose-stimulated HAECs were incubated
with an anti-ICAM-1 antibody at 5 μg/ml for 30 minutes
prior to the adhesion assay. As shown in Figure 2D, the
adhesion of THP-1 cells to high-glucose-stimulated
HAECs was significantly suppressed by anti-ICAM-1
antibody (21.4% inhibition, p< 0.05), but not by a non-
specific goat serum IgG antibody. Taken the above to-
gether, it suggested that long-term exposure to high
glucose, probably via the osmotic effects, may enhance
endothelial adhesiveness to monocytes by increasing
endothelial ICAM-1 expression.
IL-6 contributes to high glucose- or mannitol-induced
endothelial adhesiveness to monocytes
In the present study, long-term incubation with high glu-
cose increased IL-6 production, which may increase
monocyte-endothelial interaction [18]. In this study, in-
cubation of HAECs with high glucose or mannitol for
4 days similarly and significantly increased IL-6 protein
secretion in the medium (Figure 3A). Furthermore, ex-
posure to IL-6 (5 ng/ml) significantly increased ICAM-1
protein accumulation by 24% (p< 0.05) in cultured
HAECs (Figure 3B), which was compatible to the previous
suggestion that IL-6 may mediate monocyte adhesion to
activated endothelial cells [19]. Furthermore, to inhibit the
effects of endothelial-derived IL-6, the IL- 6 neutralizing
antibody was added to high-glucose treated HAECs,











































Figure 1 Time-dependent effects of high glucose (D-glucose, 25 mmol/l) on ICAM-1 & IL-6 expression in human aortic endothelial cells.
Western blotting analyses (upper panel) showed that both ICAM-1 (left lower panel) and IL-6 expression (right lower panel) were significantly
increased after high glucose treatment for 4 days through 7 days and reduced after 14 days. N = 4 in each set of experiment. * p< 0.05 compared
to day 0.
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the crucial role of endothelial-derived IL-6 in either
high-glucose or mannitol-induced endothelial adhesiveness
to monocytes.GBE inhibits ROS generation, IL-6 and ICAM-1 expression,
and the adhesiveness to monocytes in high-glucose- or
mannitol-stimulated HAECs
It has been suggested that hyperglycemia may induce
endothelial ROS generation [20]. N-acetylcysteine (NAC),
an antioxidant, was shown to abolish high-glucose-
induced oxidative stress and adhesion molecule expression
in endothelial cells [21]. In the present study, intracellular
ROS generation was significantly increased by high glu-
cose, which could be inhibited by pretreatment with GBE
(100 μg/ml) or NAC (1 mmol/l) (Figure 4A). On the other
hand, pretreatment with GBE (100 μg/ml) or NAC
(1 mmol/l) for 1 day significantly inhibited the adhesion of
THP-1 cells to high-glucose- or mannitol-activated
HAECs (Figure 4B). Western blot and ELISA study also
showed that pretreatment with GBE (100 μg/ml) or NAC
(1 mmol/l) significantly and similarly suppressed glucose-
induced endothelial ICAM-1 expression (Figure 4C) and
IL-6 secretion in the conditioned medium (Figure 4D) re-
spectively. Finally, GBE directly inhibited IL-6-induced
ICAM-1 expression in HAECs (Figure 4E). These findings
indicate that GBE, probably by its antioxidant capacity,
may inhibit high-glucose-activated IL-6 secretion and con-
sequent ICAM-1-mediated endothelial adhesiveness to
monocytes.STAT3 is involved in high-glucose- and mannitol-induced
ICAM-1 accumulation in HAECs
Several transcription pathways may be involved in the acti-
vation of ICAM-1 in endothelial cells. Our preliminary data
showed that both AP-1 and NF-κB could be activated with
increased nuclear expression by high glucose or by mannitol
in HAECs. However, while significantly reduced ICAM-1
expression, treatment with GBE did not significantly modify
the activation of either AP-1 or NF-κB in the presence of
high glucose or mannitol (Additional file 1: Figure S1). It
seems that other transcription pathways may be more rele-
vant to ICAM-1 induction in current study model.
Another principle factor of this regulatory mechanism
is the transcription factor STAT3, which forms either
homodimers or heterodimers with STAT1 and translo-
cates into the nucleus [4]. In this study, treatment with
piceatannol, a STAT1/3 inhibitor, but not fludarabine, a
STAT1 inhibitor, could significantly suppress glucose-
induced protein expression of ICAM-1 (Figure 5A). On
the other hand, the combination of fludarabine but not
piceatannol with GBE significantly suppressed glucose-
induced ICAM-1 expression (Figure 5B). The above find-
ings suggest that STAT3 might play the crucial role in
high-glucose-induced ICAM-1 expression in HAECs.GBE inhibits high-glucose-induced activation of STAT1
and STAT3
It was suggested that redox-related transcriptional regula-
tion may be involved in the activation of STAT1/3 for the
induction of ICAM-1 genes [22]. The results of EMSAs
Figure 2 Cell viability reduction, ICAM-1 expression, and monocyte–endothelial cell adhesion mediated by high glucose in HAECs. (A)
HAECs were treated with D-glucose (25 mM) or osmotic effect control mannitol (20 mM) for 4 days. (B) HAECs were incubated in glucose for 0, 1,
4, and 7 days. Cell lysates of ICAM-1 were determined by western blotting. (C) THP-1 was labeled with BCECF-AM and adhered to HAECs in
response to normal-glucose, high-glucose, and mannitol treatment for 4 days. (D) HAECs in response to high-glucose and mannitol treatment for
4 days followed by neutralization with ICAM-1 antibody for 30 min (5 μg/ml). N = 8 in each set of experiment. *p< 0.05 compared to control
group; #p< 0.05 compared to high-glucose or mannitol groups.
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resulted in the band shifts of both STAT1 and STAT3.
These band shifts were specific for STAT1 and STAT3
binding because they were undetectable when a 100-fold
excess of unlabeled STAT1 and STAT3 oligonucleotide was
present (data not shown). Treatment with GBE (100 μg/ml)
or NAC significantly inhibited the activation of STAT1 and
STAT3 induced by high glucose or by mannitol (Figures 5C
and 5D). Treatment with the IL-6 neutralizing antibody
also significantly reduced high-glucose- or mannitol-
induced STAT1/3 activation (data not shown). Accord-
ingly, IL-6 mediated, redox-related, STAT3 transcription
pathways are critical to ICAM-1 induction in HAECs.
GBE could attenuate high-glucose- or mannitol-induced
ICAM-1 expression by inhibiting STAT1/3 activation.Discussion
This study reveals several major findings. First, treatment of
HAECs with high glucose for 4 days significantly increased
endothelial ICAM-1 expression, which in turn enhanced
endothelial adhesiveness to monocytes. Second, long-term
presence of high glucose stimulated endothelial IL-6 secre-
tion via the redox-dependent mechanism, which may then
induce STAT3 activation and consequent ICAM-1 expres-
sion. Third, in parallel to high glucose, mannitol exerted the
similar effects on inducing endothelial adhesiveness. Fourth,
pretreatment with GBE inhibited high-glucose- as well
as mannitol-induced intracellular ROS production, IL-6 se-
cretion, STAT3 activation, ICAM-1 accumulation, and con-
sequent endothelial adhesiveness to monocytes. Fifth, in
parallel to GBE, NAC also exerted the similar endothelial
Figure 3 IL-6 production contributes to glucose-induced monocyte adhesiveness to HAECs. (A) HAECs were responsive to high glucose
and mannitol for 4 days. The conditioned medium was isolated, and IL-6 expression was determined by ELISA. (B) HAECs were incubated with
5 ng/ml of IL-6 cytokine for 24 h. The presence of ICAM-1 in cell lysates was determined by western blotting. (C) HAECs were responsive to high
glucose and mannitol for 3 days, followed by treatment with IL-6 antibody for 1 day (5 μg/ml). N = 6 in each set of experiment. *p< 0.05
compared to control group; #p< 0.05 compared to high-glucose or mannitol groups.
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tol. Taken together, it is suggested that long-term presence
of high glucose might induce STAT3-mediated ICAM-1-
dependent endothelial adhesiveness to monocytes, which
requires the osmotic-related redox-dependent IL-6 activa-
tion. Furthermore, GBE, an antioxidant herb medicine,
could prevent high-glucose-induced endothelial inflamma-
tion mainly by inhibiting IL-6 activation.
Hyperglycemia is considered one of the major patho-
genic factors for atherogenesis and the progression of
atherosclerosis in diabetes mellitus [23]. However, the
detailed molecular pathological mechanisms may be var-
ied according to the different findings in previous
in vitro and in vivo studies. In the current study, endo-
thelial ICAM-1 expression was increased by chronictreatment with high glucose, resulting in the upregulation
of endothelial adhesiveness to monocytes. Our findings
agreed in part with the previous suggestion that ICAM-1
may play an essential role in mediating endothelial adhe-
siveness to monocytes [24]. Besides, in the present study,
long-term presence of high glucose increased endothelial
IL-6 expression at least in part via the oxidative related
mechanisms, which may then contribute to the increase of
endothelial adhesiveness to monocytes. These findings also
agreed in part with that of previous studies with different
study designs, in which IL-6 was shown to induce endothe-
lial ICAM-1 expression [25] and oxidative stress could be
involved in the induction of IL-6 and ICAM-1 in HAECs
treated with intermittent high glucose [26]. Finally, in the
current study, both high glucose and mannitol could induce
Figure 4 GBE inhibits high-glucose-induced ROS generation, IL-6 and ICAM-1 expression, and monocyte adhesiveness to HAECs. (A)
HAECs were incubated in high glucose or mannitol for 3 days, followed by incubation with GBE (100 μg/ml) or NAC (1 mmol/l), an antioxidant
agent, for 1 day. (B) THP-1 labeled with BCECF-AM adhered to HAECs in response to high-glucose or mannitol treatment for 3 days, followed by
addition of GBE or NAC for 1 day. (C) HAECs were incubated in high glucose or mannitol for 3 days, followed by incubation in GBE and NAC for
1 day. (D) HAECs were incubated in glucose or mannitol for 3 days, followed by incubation with GBE or NAC for 1 day. Human IL-6 secreted into
the medium was measured using ELISA. (E) HAECs were incubated with GBE for 30 min, followed by treatment with IL-6 (5 ng/ml) cytokine for
24 h. The presence of ICAM-1 was determined by western blotting. N = 6 in each set of experiment. *p< 0.05 compared to control group;
#p< 0.05 compared to high-glucose or mannitol groups.
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suggestion that high glucose may increase endothelial
ICAM-1 expression by a nonspecific osmotic effect [6].
More interestingly, such effects on endothelial ICAM-1 ex-
pression could be reversible and directly related to the pres-
ence of high glucose since it could disappear gradually after
high-glucose medium was replaced by normal medium
(please see Additional file 1: Figure S3). Most mammalian
cells respond to changes in cellular volume with a net
movement of water driven by a redistribution of salt and or
small organic molecules [27,28]. However, it is still not
known which receptor or sensor for osmotic effect may
regulate cell volume as well as cell signal transduction in
endothelial cell. One of the possible receptors is receptor
tyrosine kinase receptors (RTKs). Growth control and
apoptosis in mammalian cells are highly regulated by
RTKs. A number of reports also implicated a role of RTKsin osmosensing and volume control as upstream regula-
tors. That osmotic stress activates p38 MAPK and JNK
were described in mammalian cells [29-31]. Accordingly,
our study connected the complex findings of previous
studies and helped to elucidate a whole picture of detailed
mechanisms for high-glucose-induced endothelial adhe-
siveness that mimics early in vivo atherogenesis.
It was recently shown that Interleukin-6 (IL-6) plays a
beneficial role in anti-inflammatory activity to against bac-
terial infections [32], and enhances insulin action immedi-
ately at early recovery [33,34]. However, it is well known
that IL-6 is a multifunctional cytokine regulating cellular
responses especially in inflammation. It has been suggested
that diabetes-related oxidative stress may induce vascular
IL-6 expression and activate IL-6R and gp130, which in turn
activates the JAK2/STAT3 signaling cascade [35]. In the
present study, STAT1 and STAT3 rather than AP-1 and
Figure 5 GBE inhibits high-glucose-induced activation of STAT1 and STAT3 as well as ICAM-1 accumulation in HAECs. (A) HAECs were
incubated in high glucose for 3 days, followed by incubation with GBE, fludarabine (STAT1 inhibitor;20 μmol/l), or piceatannol (10 μmol/l) for
1 day. (B) HAECs were incubated in high glucose for 3 days, followed by incubation with GBE, fludarabine, piceatannol, fludarabine plus GBE, or
piceatannol plus GBE for 1 day. (C and D) EMSAs for STAT1 and STAT3 were performed using nuclear extracts from human aortic endothelial cells
that were cultured in high glucose or mannitol for 3 days, followed by treatment with GBE. Quantification of STAT1 and STAT3 activation in
HAECs treated with high glucose combined with GBE is also shown. N = 6 in each set of experiment. *p< 0.05 compared to control group;
# p< 0.05 compared to the high-glucose or mannitol groups.
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importantly, piceatannol, a STAT1/3 inhibitor, but not flu-
darabine, a STAT1 inhibitor, significantly suppressed
high-glucose-induced ICAM-1 expression in HAECs, sug-
gesting the contribution of STAT3 pathways in ICAM-1
induction. It has been previously shown that IL-6 may ac-
tivate endothelial STAT3 and ICAM-1 expression [25].
The present study further indicated that long-term pres-
ence of high glucose may induce endothelial IL-6 produc-
tion by the osmotic-related redox-dependent mechanisms,which in turn activate endothelial ICAM-1 expression
mainly via the STAT3 transcriptional pathways. Our find-
ings support the rationale that strict glucose control may
be critical to reduce osmotic injury and related oxidative
stress for endothelial protection in clinical hyperglycemia.
There have been very few, mainly in vitro, evidence for
the effects of GBE in the presence of high glucose [36].
To our knowledge, this is the first study demonstrating
the direct endothelial protection effects of GBE in the
presence of long-term high glucose. In this study,
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HG-induced ICAM-1 accumulation in HAECs. (Add-
itional file 1: Figure S2) It was also shown that NAC, simi-
lar to GBE, could also reduce high-glucose-induced ROS
generation, IL-6 secretion, and ICAM-1 accumulation in
HAECs. Taken together, our findings suggest that GBE, as
an antioxidant herb medicine, may inhibit IL-6 activation
and consequent ICAM-1 expression probably by its antioxi-
dant as well as anti-inflammatory effect. It was recently
shown that GBE may have anti-oxidant ability by its free
radical scavenger property [37] and mitochondrial uncoup-
ling effect [38]. However, high dosage GBE (50–200 μg/mL)
didn’t reduce hydrogen peroxide generation by mitochon-
dria in rats heart [39], which may be due to the complex
components of GBE and its selective uncoupling of mito-
chondrial oxidative phosphorylation. Future studies are
required to validate the current findings in in vivo
hyperglycemia.
The detailed mechanisms of the anti-inflammatory
effects of GBE for vascular protection might be complex
and varied in different experimental as well as clinical
conditions. We have recently shown the contribution of
Nrf-2-mediated heme oxygenase 1 induction to the in-
hibitory effects of GBE on TNF-α-induced VCAM-1 ex-
pression in endothelial cells [14]. In the present study,
GBE was shown to inhibit high-glucose-induced ICAM-1
expression and consequent adhesiveness of HAECs. These
findings are in line with our previous findings that GBE
could inhibit cytokine-stimulated endothelial adhesiveness
[13], vascular smooth muscle cell proliferation [40], and
in vivo neointimal hyperplasia [12] mainly by its inhibitory
effects on intracellular oxidative stress. Though the mo-
lecular mechanisms could be different, GBE may have
similar anti-inflammatory effects in either TNF-α-induced
or high-glucose-induced endothelial adhesiveness, suggest-
ing the potential universal role of GBE in endothelial pro-
tection. However, given the complex and multiple effects
of GBE shown in the current and previous studies [12-14],
it is possible that other redox-independent mechanisms
may be also involved in the beneficial effects of GBE on
endothelial protection in the presence of high glucose. It
might be important since the pathological changes are
much more complex in in vivo hyperglycemia. Future
in vivo studies are required to clarify this issue.
It should be indicated that GBE used in the current
and our previous studies is the same preparation with
fixed portions of standard components [12-14]. Though
the individual effects of the major components of GBE,
flavone glycoside and terpenlactones, on atherogenesis
and vascular inflammation remain to be investigated, the
dosage of GBE used in the current study is similar to or
equivalent to that had been used in our previous in vitro
and in vivo studies [12-14]. Furthermore, it was shown
in the previous study that in the volunteers, afteradministration of GBE (160 mg) in free (Ginkgoselect) or
phospholipid complex (Ginkgoselect Phytosome) forms,
the maximum plasma concentrations, C(max), of total
ginkgolides A, B and bilobalide were 85.0 and 181.8 ng/mL
for Ginkgoselect and Ginkgoselect Phytosome, respectively.
The C(max) values reached at 120 minutes for the free
form and at 180–240 minutes for the phospholipid com-
plex form [41]. In such case, the serum level seems similar
to the concentration used in the current and previous stud-
ies. As that had been mentioned previously, the dose of
GBE used in the current and previous studies may not be
directly translated to that in clinical situations since there
might be significant variety in individual drug metabolism
and accumulation effects of such kind of herb medicine in
different person [12,13]. However, the GBE and NAC used
in the current study have also been widely and safely used
clinically for years. Future in vivo studies or even clinical
trials seem feasible to test the potential role and investigate
the proper dose of GBE and other antioxidant/anti-
inflammatory agents such as NAC for vascular protection
especially in patients with chronic hyperglycemia and ele-
vated serum IL-6 levels.
Conclusions
Chronic exposure to high glucose can induce endothelial
ROS production, stimulate IL-6 expression, activate
STAT1 and STAT3, increase ICAM-1 expression, and en-
hance endothelial adhesiveness to monocytes at least in
part by its osmotic effects. Treatment with GBE, a clinic-
ally used herbal antioxidant, may inhibit high-glucose-
induced IL-6 release and ICAM-1 accumulation, leading
to a reduction in endothelial adhesiveness to monocytes.
Our findings might help to elucidate the complex molecu-
lar mechanisms of high-glucose-induced endothelial in-
flammation and provide the potential rationale to strict
glucose control and potential antioxidant therapeutic strat-
egy targeting on IL-6 for endothelial protection in the
presence of hyperglycemia. Future in vivo study is still
indicated for proper dosing before the above therapeutic
strategy may be validated clinically.
Additional fileAdditional file 1: Figure S1. Pretreatment with GBE had no significant
effects on high-glucose-induced AP-1 and NF-κB activation in HEACs. Figure S2.
Pretreatment with GBE does-dependently suppressed high glucose-induced
ICAM-1 accumulation in HAECs. Figure S3. Endothelial ICAM-1 expression was
increased by high-glucose (25 mM) stimulation for 4 days, which was losing
after the replacement of normal glucose medium (5 mM) for 1–4 days.
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